News News January 27, 2021 Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study Read more December 22, 2020 Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection Read more November 9, 2020 Notice on email address domain changing Read more October 6, 2020 First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval Read more September 29, 2020 Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic Read more August 13, 2020 Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility Read more June 30, 2020 Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing Read more June 2, 2020 Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India Read more May 27, 2020 Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19 Read more May 5, 2020 Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials Read more April 30, 2020 Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic Read more March 10, 2020 Ajinomoto Bio-Pharma Services Announces Formation of External Advisory Board Read more Loading…Load More Althea Technologies Announces Expanded Roles for Key Executives Previous Page 1 … 6 7 8